AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 18 - (NewsRx.com & NewsRx.net) --
Biomira, Inc. (BIOM, BRA) announced March 30, 2001, that it had terminated its agreement with Biovector Therapeutics, SA of Toulouse, France, for the co-development of Biomira's idiotypic vaccine against B-cell lymphoma.
Biomira's idiotypic vaccine involves the use of a patient's own cancerous cells to develop a highly specific vaccine. Biomira plans to pursue this autologous vaccine program independently.
Biomira completed enrollment of the Idiotypic Vaccine Phase I trial with 10 evaluable patients with follicular lymphoma. The objective of the trial was to establish safety and immune response profiles. Prior to study entry, patients had undergone chemotherapy and achieved either full remission or a 90% partial response. The vaccine was administered via subcutaneous ...
Source: HighBeam Research, Biomira To Proceed Independently With Autologous Vaccine...